The German medtech giant announced last week that its Atellica IM high-sensitivity troponin I (TnIH) blood test has secured a new claim extending prognosis up to one year in advance. The test is meant to predict the risk of major cardiac events and death.
According to Siemens Healthineers, Atellica IM is the first test of its kind in the United States to receive FDA clearance for such a one-year prognosis. The company said many U.S. hospitals already use the Atellica IM TnIH blood test to measure people’s cardiac troponin I — a specific and sensitive biomarker that indicates heart muscle injury.